Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Genetic Diseases, Inborn 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Melphalan 3sargramostim 1romidepsin 1montanide ISA 51 1keyhole-limpet hemocyanin 1detox adjuvant 1Waiting Lists 1Thalidomide 1Radiosurgery 1Radiation 1Leucovorin 1Ketoconazole 1Interleukin-2 1Floxuridine 1FANG vaccine 1Docetaxel 1Alendronate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Genetic Diseases, Inborn × keyhole-limpet hemocyanin × Clear all
NCT00019097 2024-03-04

Vaccine Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms, Genetic Diseases, Inborn, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡